How Much Does Crestor (Rosuvastatin) Cost in Kansas in 2026?

Brand vs. Generic Rosuvastatin Pricing in Kansas

The gap between brand-name Crestor and its generic equivalent in Kansas is substantial. AstraZeneca's list price for Crestor sits near $290 per month in 2026, but generic rosuvastatin calcium tablets average roughly $15 per month across Kansas retail pharmacies. That is a 95% cost reduction.

Why the Price Dropped So Sharply

Crestor lost its U.S. Patent exclusivity in 2016. Multiple manufacturers now produce generic rosuvastatin calcium in 5 mg, 10 mg, 20 mg, and 40 mg tablets. The FDA's Orange Book lists these as therapeutically equivalent (AB-rated) to brand Crestor, meaning pharmacists in Kansas can substitute the generic automatically unless a prescriber writes "dispense as written."

Where Prices Vary Across Kansas

Pricing is not uniform. Independent pharmacies in smaller Kansas communities (Dodge City, Liberal, Garden City) may charge $8 to $12 per month for generic rosuvastatin when purchased with a discount coupon. Larger chain pharmacies in Wichita, Overland Park, and Kansas City (KS) tend to cluster near the $15 average. Specialty or compounding pharmacies operate on a different pricing structure entirely (discussed below).

Cash Pay vs. Insurance Copay

For patients paying cash, $15 per month is often cheaper than an insurance copay. Many commercial plans set generic tier 1 copays at $10 to $20, which means using a GoodRx-style discount card and paying out of pocket can match or beat the insurance price. The practical advice: compare your plan copay against the cash-pay price before defaulting to insurance billing.

Kansas Medicaid and Rosuvastatin Coverage

Kansas Medicaid (KanCare) does not cover Crestor or generic rosuvastatin for primary hyperlipidemia or ASCVD prevention as of 2026. Coverage is limited to patients with a type 2 diabetes diagnosis.

What "T2D Only" Means in Practice

If a Kansas Medicaid beneficiary has both type 2 diabetes and dyslipidemia, rosuvastatin may be approved. The prescriber must document the diabetes diagnosis as a qualifying condition. A standalone hyperlipidemia diagnosis will result in a pharmacy claim denial. This restriction follows KanCare's preferred drug list (PDL), which categorizes HMG-CoA reductase inhibitors by indication.

Alternatives for Medicaid Patients Without Diabetes

Kansas Medicaid does cover other statins for primary hyperlipidemia. Atorvastatin (generic Lipitor) and simvastatin (generic Zocor) are typically on the KanCare preferred drug list without prior authorization for lipid-lowering indications. Rosuvastatin and atorvastatin show comparable LDL-lowering efficacy at equipotent doses. A 2016 meta-analysis published in the European Journal of Preventive Cardiology (N=32,258 across 15 trials) found no statistically significant difference in major adverse cardiovascular events between the two drugs at equivalent intensity 1.

Filing a KanCare Exception

Patients who need rosuvastatin specifically (for example, due to documented atorvastatin intolerance or CYP3A4 drug interactions) can request a prior authorization exception. The prescriber submits clinical documentation to the KanCare managed care organization. Approval rates for statin PA requests are not publicly reported by Kansas, but the process typically takes 24 to 72 hours.

Insurance Coverage for Crestor in Kansas

Most commercial insurance plans in Kansas cover generic rosuvastatin on their lowest formulary tier. Brand Crestor is a different situation.

Commercial Plans

Blue Cross Blue Shield of Kansas, Aetna, UnitedHealthcare, and Cigna plans sold on the Kansas marketplace generally place generic rosuvastatin on tier 1 (preferred generic), with copays between $0 and $20 per month. Brand Crestor, when covered, sits on tier 3 or tier 4 (non-preferred brand), with copays of $50 to $100 or higher. Some plans require step therapy: the patient must try and fail generic rosuvastatin before brand Crestor is authorized.

Medicare Part D in Kansas

Medicare Part D plans available in Kansas overwhelmingly cover generic rosuvastatin. The 2026 Inflation Reduction Act cap of $2,000 on annual out-of-pocket Part D spending applies, which benefits patients on multiple medications. For rosuvastatin specifically, most Part D plans charge $1 to $10 per month for the generic. The Medicare Plan Finder allows Kansas residents to compare formulary placement by zip code.

Employer-Sponsored Plans

Large Kansas employers (Sprint/T-Mobile, Cerner/Oracle Health, Garmin) typically offer plans with $0 generic copays through mail-order pharmacy. A 90-day supply of generic rosuvastatin via mail order often costs $0 to $15 total, making it the cheapest option for employed Kansans with benefits.

Compounded Rosuvastatin in Kansas

Compounded rosuvastatin is legal in Kansas through licensed 503A compounding pharmacies. This is worth understanding, even if most patients will not need it.

What 503A Compounding Means

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist can compound a drug for an individual patient with a valid prescription. The compounded product must differ meaningfully from the commercially available version (different dose, different form, or removal of an allergen). Kansas follows this federal framework without additional state-level restrictions on statin compounding.

When Compounding Makes Sense

Compounded rosuvastatin might be appropriate for patients who need a non-standard dose (say, 7.5 mg), a liquid suspension (for patients who cannot swallow tablets), or a formulation free of specific inactive ingredients like lactose. It is not a cost-saving measure for most patients. The generic tablet at $15 per month is already inexpensive.

Cost and Access

Some Kansas 503A pharmacies advertise compounded rosuvastatin at very low prices, occasionally listed as $0 with a subscription model where the patient pays a flat monthly membership fee instead. Verify that any compounding pharmacy holds a current Kansas Board of Pharmacy license and is operating under a valid 503A exemption before filling a prescription.

Telehealth Prescribing of Rosuvastatin in Kansas

Kansas permits telehealth prescribing of rosuvastatin without geographic restriction. A provider licensed in Kansas can evaluate a patient via video or audio-only visit and prescribe a statin if clinically appropriate.

Kansas Telehealth Parity Law

Kansas enacted telehealth parity legislation (K.S.A. 40-2,215) requiring commercial insurers to cover telehealth visits at the same rate as in-person visits. This means the consultation to obtain a rosuvastatin prescription is reimbursable at standard rates. Medicaid (KanCare) also covers telehealth visits.

How It Works in Practice

A patient in rural western Kansas (where the nearest cardiologist may be 90+ miles away) can see a licensed provider via a telehealth platform, get a lipid panel ordered at a local lab, and receive a rosuvastatin prescription sent to their pharmacy. The entire process, from scheduling to medication pickup, can happen within 48 to 72 hours.

Platforms Available to Kansas Residents

HealthRX and similar telehealth platforms serve Kansas residents statewide. The prescribing provider must hold an active Kansas medical license. Interstate medical licensure compact (IMLC) members can also prescribe across state lines, and Kansas is an IMLC member state as of 2021.

Clinical Evidence Supporting Rosuvastatin

Rosuvastatin is one of the most extensively studied statins in cardiovascular medicine. Two landmark trials define its evidence base.

JUPITER Trial

The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), published in the New England Journal of Medicine in 2008, enrolled 17,802 apparently healthy participants with LDL cholesterol <130 mg/dL and high-sensitivity C-reactive protein ≥2.0 mg/L 2. Rosuvastatin 20 mg daily reduced the primary composite endpoint (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death) by 44% compared with placebo (hazard ratio 0.56; 95% CI, 0.46 to 0.69; P<0.00001).

The trial was stopped early at a median follow-up of 1.9 years because the treatment benefit crossed the prespecified stopping boundary. LDL cholesterol fell by 50% and hsCRP by 37% in the rosuvastatin group.

2018 AHA/ACC Cholesterol Guidelines

The 2018 American Heart Association and American College of Cardiology guideline on the management of blood cholesterol classifies rosuvastatin 20 to 40 mg as a "high-intensity" statin, expected to lower LDL-C by ≥50% 3. The guideline recommends high-intensity statin therapy for adults with clinical ASCVD, LDL-C ≥190 mg/dL, diabetes aged 40 to 75, or a 10-year ASCVD risk ≥7.5% with enhancing risk factors. Rosuvastatin 20 mg and atorvastatin 40 to 80 mg are the two drugs that meet the high-intensity threshold.

Dr. Scott Grundy, lead author of the 2018 AHA/ACC cholesterol guideline, stated: "For patients who need aggressive LDL lowering, rosuvastatin and atorvastatin at high-intensity doses remain the foundation of therapy. The evidence base for these two agents is the strongest in the statin class."

METEOR Trial

The METEOR trial (Measuring Effects on Intima-Media Thickness: an Evaluation of Rosuvastatin) demonstrated that rosuvastatin 40 mg slowed progression of carotid intima-media thickness in low-risk patients with subclinical atherosclerosis over 2 years, compared with placebo (annualized rate of change: -0.0014 mm/year vs. +0.0131 mm/year; P<0.001) 4.

Discount Programs and Savings Cards

Several mechanisms exist to reduce rosuvastatin costs for Kansas patients who are uninsured or underinsured.

Manufacturer Savings Programs

AstraZeneca historically offered a Crestor savings card for commercially insured patients, reducing copays to as low as $3 per month. With generic rosuvastatin widely available and priced under $20, the brand savings card is less relevant than it was pre-2016. Check AstraZeneca's patient assistance page for current program availability.

Pharmacy Discount Cards

GoodRx, RxSaver, and SingleCare consistently show Kansas prices for generic rosuvastatin 10 mg (#30 tablets) between $8 and $18. These are free discount programs, not insurance. They work at most Kansas chain pharmacies (CVS, Walgreens, Walmart, Dillons/Kroger). The discount is applied at point of sale and cannot be combined with insurance billing.

$4 Generic Lists

Walmart and Dillons (Kroger) pharmacies in Kansas include generic rosuvastatin on their $4 to $10 generic drug lists for a 30-day supply. A 90-day supply runs $10 to $24. This is often the absolute lowest price available without a coupon.

The American Heart Association's My Life Check calculator recommends that patients discuss statin cost barriers with their provider, as even small copays can reduce long-term adherence.

Patient Assistance Programs for Brand Crestor

AstraZeneca's AZ&Me Prescription Savings Program provides brand Crestor at no cost to qualifying uninsured patients with household income below 400% of the federal poverty level. Applications require proof of income, a valid prescription, and U.S. Residency. Processing takes 4 to 6 weeks 5.

Dosing, Monitoring, and Practical Considerations

Standard Dosing

Rosuvastatin is dosed once daily, with or without food. The FDA-approved prescribing information specifies a starting dose of 10 to 20 mg for most adults, with a maximum dose of 40 mg. The 40 mg dose is reserved for patients who do not reach their LDL-C goal on 20 mg.

Asian-descent patients should start at 5 mg due to higher systemic exposure (approximately 2-fold increase in rosuvastatin AUC observed in pharmacokinetic studies), per FDA labeling 6.

Monitoring Schedule

Baseline labs before starting: fasting lipid panel, hepatic transaminases (ALT), and fasting glucose or HbA1c. The 2018 AHA/ACC guideline recommends a repeat fasting lipid panel at 4 to 12 weeks after initiation to assess LDL-C response and adherence 3. Annual lipid panels thereafter are standard practice.

Side Effects Relevant to Cost Decisions

Myalgia occurs in roughly 5% to 10% of statin users across the class, though the STOMP trial (Effect of Statins on Skeletal Muscle Function, N=420) found no significant difference in muscle pain between rosuvastatin 20 mg and placebo over 6 months 7. If a patient experiences perceived statin intolerance and switches to a more expensive alternative (ezetimibe, PCSK9 inhibitor), cost implications escalate sharply. Ezetimibe adds $15 to $30 per month; evolocumab (Repatha) or alirocumab (Praluent) can exceed $500 per month even after copay assistance.

Dr. Steven Nissen, Chief Academic Officer at the Cleveland Clinic Heart, Vascular & Thoracic Institute, has noted: "The nocebo effect accounts for a significant proportion of statin intolerance reports. Before abandoning a $15-per-month generic statin for a $500-per-month biologic, clinicians should rechallenge with the same statin or try an alternate statin at a lower dose."

Kansas-Specific Pharmacy and Regulatory Notes

Kansas Board of Pharmacy

The Kansas State Board of Pharmacy licenses all retail, mail-order, and compounding pharmacies operating in the state. Patients can verify a pharmacy's license status through the Board's online lookup tool. Compounding pharmacies must additionally comply with USP <795> (non-sterile) or USP <797> (sterile) standards.

No State-Level Price Controls

Kansas does not impose state-level drug price controls or transparency reporting requirements for generic drugs as of 2026. Pricing is determined by market competition among wholesalers and pharmacies. The practical effect: prices can vary 50% or more between pharmacies in the same city.

Kansas Prescription Drug Monitoring Program

Rosuvastatin is not a controlled substance and is not tracked through the Kansas PDMP (K-TRACS). There are no quantity limits or refill restrictions beyond standard prescription validity (one year from the date written for non-controlled medications in Kansas).